Outlook Therapeutics, Inc. (OTLK): R&D Expense
$27.18M
Year ended 2025-09-30
$17.36M
Trailing 12 months to 2026-06-30
-13.7%
3-year compound annual growth
+0.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $27.18M | -34.9% | 2025-12-19, From 2024-10-01 |
| 2024-09-30 | $41.76M | +57.9% | 2025-12-19, From 2023-10-01 |
| 2023-09-30 | $26.45M | -37.5% | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | $42.33M | +8.7% | 2023-12-22, From 2021-10-01 |
| 2021-09-30 | $38.96M | +47.9% | 2022-12-29, From 2020-10-01 |
| 2020-09-30 | $26.34M | +10.7% | 2021-12-23, From 2019-10-01 |
| 2019-09-30 | $23.81M | +28.6% | 2020-12-23, From 2018-10-01 |
| 2018-09-30 | $18.50M | -22.3% | 2019-12-19, From 2017-10-01 |
| 2017-09-30 | $23.81M | -27.3% | 2018-12-18, From 2016-10-01 |
| 2016-09-30 | $32.76M | n/c | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | $38.88M | n/a | 2016-12-29, From 2014-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $15.09M | +17.4% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $28.52M | -11.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗